Whereas most patients with primary melanoma are cured with surgery alone, patients with metastatic melanoma often show an initial favorable response to BRAF- and MEK-targeted therapies [8,9] and/or immune-checkpoint inhibitors (ICIs) [10,11], and eventually develop disease progression due to intrinsic or acquired resistance mechanisms [12,13,14,15]. Here, MAP2K7 is linked to melanoma.